CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.
Revenue (Most Recent Fiscal Year) | $371.21M |
Net Income (Most Recent Fiscal Year) | $-153.61M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 28.92 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.45 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -40.60% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -8.09% |
Return on Assets (Trailing 12 Months) | -6.73% |
Current Ratio (Most Recent Fiscal Quarter) | 17.54 |
Quick Ratio (Most Recent Fiscal Quarter) | 17.54 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $23.70 |
Earnings per Share (Most Recent Fiscal Quarter) | $1.10 |
Earnings per Share (Most Recent Fiscal Year) | $-1.94 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.96 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 84.88M |
Free Float | 81.40M |
Market Capitalization | $4.92B |
Average Volume (Last 20 Days) | 1.19M |
Beta (Past 60 Months) | 1.76 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
Percentage Held By Institutions (Latest 13F Reports) | 69.20% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |